Home » Stocks » ACAD

ACADIA Pharmaceuticals Inc. (ACAD)

Stock Price: $21.15 USD 0.08 (0.38%)
Updated May 10, 2021 1:35 PM EDT - Market open
Market Cap 3.37B
Revenue (ttm) 458.24M
Net Income (ttm) -260.01M
Shares Out 160.01M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $21.15
Previous Close $21.07
Change ($) 0.08
Change (%) 0.38%
Day's Open 20.90
Day's Range 20.62 - 21.27
Day's Volume 579,261
52-Week Range 19.20 - 58.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - May 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia...

3 days ago - Newsfile Corp

ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.

4 days ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - May 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) all...

4 days ago - Newsfile Corp

Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - May 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia...

4 days ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - May 5, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June...

4 days ago - Newsfile Corp

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021. “NUPLAZID delivered strong year-over-year perfor...

4 days ago - Business Wire

New York, New York--(Newsfile Corp. - May 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and...

5 days ago - Newsfile Corp

LOS ANGELES, May 4, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acad...

6 days ago - PRNewsWire

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: BofA Securities 2021 Health Care Conference Firesid...

6 days ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $acad #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on beh...

1 week ago - Business Wire

San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: Ju...

1 week ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Co...

1 week ago - Business Wire

New York, New York--(Newsfile Corp. - April 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) ...

1 week ago - Newsfile Corp

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceutical...

1 week ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc....

1 week ago - Business Wire

New York, New York--(Newsfile Corp. - April 27, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceutic...

1 week ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors

1 week ago - Business Wire

LOS ANGELES, April 26, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia...

2 weeks ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $acad #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf o...

2 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $ACAD #ClassAction--Shareholder rights law firm Robbins LLP is investigating Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on behalf of shareholders to determine whether cert...

2 weeks ago - Business Wire

San Francisco, California--(Newsfile Corp. - April 23, 2021) -  Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: ...

2 weeks ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $acad #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Acadia Pharmaceuticals Inc...

2 weeks ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACAD #ACAD--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

2 weeks ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACAD #ACAD--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

2 weeks ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACAD #investors--The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors

2 weeks ago - Business Wire

NEW YORK, April 22, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACA...

2 weeks ago - PRNewsWire

SAN FRANCISCO, April 22, 2021 /PRNewswire/ -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.  Class Period: June 15, 2020 - A...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) ...

2 weeks ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $ACAD #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) inves...

2 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after the close of the U.S. fin...

2 weeks ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #AcadiaPharmaceuticals--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United S...

2 weeks ago - Business Wire

NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of i...

2 weeks ago - PRNewsWire

San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is i...

3 weeks ago - Newsfile Corp

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ALXN, AZN, BIIB, BNTX, CRSP, EDIT ...
1 month ago - Investors Business Daily

San Francisco, California--(Newsfile Corp. - April 8, 2021) - Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is in...

1 month ago - Newsfile Corp

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia dru...

1 month ago - Benzinga

The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.

1 month ago - Zacks Investment Research

MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).  The investigation results from inaccurate statements Acadia may have ...

1 month ago - PRNewsWire

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possi...

1 month ago - PRNewsWire

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...

Other stocks mentioned: BPTH, CDTX
1 month ago - Benzinga

The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application (for Nuplazid (pimavanserin) for the treatment of halluc...

1 month ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) reg...

1 month ago - Business Wire

They've both taken a beating, but their fortunes may soon change.

Other stocks mentioned: SUPN
1 month ago - The Motley Fool

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 month ago - Zacks Investment Research

We believe that ACADIA Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades near $27 currently and it is,...

1 month ago - Forbes

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such inves...

1 month ago - Newsfile Corp

With the trading day more than halfway over, the broad markets were pushing higher yet again.

Other stocks mentioned: DKNG, HRB, NVS, BLUE, BNED, LUNG, SNDL ...
2 months ago - 24/7 Wall Street

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive a... [Read more...]

Industry
Biotechnology
IPO Date
May 27, 2004
CEO
Stephen Davis
Employees
601
Stock Exchange
NASDAQ
Ticker Symbol
ACAD
Full Company Profile

Financial Performance

In 2020, ACAD's revenue was $441.76 million, an increase of 30.28% compared to the previous year's $339.08 million. Losses were -$281.58 million, 19.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 29.11, which is an increase of 37.64% from the latest price.

Price Target
$29.11
(37.64% upside)
Analyst Consensus: Buy